New research has identified a biological mechanism that may explain why people living at higher elevations tend to develop type 2 diabetes at lower rates. Under low-oxygen conditions typical of mountain environments, the body produces fresh red blood cells that absorb significantly more glucose from the bloodstream, effectively acting as a sugar sink. The finding, reported in Cell Metabolism, offers a molecular explanation for a pattern that epidemiologists have observed across populations in the United States and South America for over a decade.
What is verified so far
The central finding comes from mouse experiments showing that hypoxia, the state of reduced oxygen availability at high altitude, triggers the body to generate new red blood cells with elevated levels of a glucose transporter called GLUT1. These freshly produced cells pull glucose out of circulation and funnel it into metabolic pathways that produce 2,3-bisphosphoglycerate (2,3-BPG), a molecule that helps hemoglobin release oxygen to tissues more efficiently. In short, the red blood cells consume extra sugar to improve oxygen delivery, a two-for-one trade that lowers blood glucose as a side effect.
Researchers at the Gladstone Institutes described the discovery process in direct terms: when mice were housed under simulated high-altitude conditions, glucose disappeared from their blood, yet none of the major organs accounted for the missing sugar. The red blood cells themselves turned out to be the destination. That result was reinforced by separate experiments at the Medical University of Vienna, where scientists raised red blood cell counts through three distinct methods: hypoxia housing, donor blood infusion, and erythropoietin (EPO) administration. All three approaches lowered blood sugar in mice, pointing to red blood cell quantity itself as a direct driver of reduced glycemia.
The laboratory results align with population-level data. A cross-sectional analysis of U.S. adults using National Health and Nutrition Examination Survey data found an inverse association between residential altitude and diabetes prevalence, even after adjusting for age, sex, and body mass index. That pattern holds beyond North America. An ecological analysis drawing on nationally representative survey data from Peru and registry data from Colombia documented a consistent inverse relationship between altitude and type 2 diabetes across two distinct Andean populations, suggesting that the association is not confined to a single country or health system.
Earlier mechanistic work laid the groundwork for the new findings. A 2023 study in Cell Metabolism established that acute and chronic hypoxia rewire systemic fuel use, redistributing how the body handles glucose and fatty acids and showing that circulating blood glucose drops under low-oxygen conditions. What remained unclear at that stage was where the glucose was going. The new Cell Metabolism paper answers that question by identifying the red blood cell compartment as the primary destination and tying the effect to specific molecular changes in GLUT1 expression and 2,3-BPG production.
What remains uncertain
The strongest evidence so far comes from mouse models, not human clinical trials. While the epidemiological data from the U.S. and Andean studies consistently show that diabetes rates are lower at higher elevations, those are observational findings. They cannot, on their own, prove that red blood cell glucose uptake is the reason. Other variables tied to altitude, including differences in diet, physical activity, temperature exposure, air pollution, and genetic adaptation among highland populations, have not been fully separated from the red blood cell mechanism.
No longitudinal human studies have tracked diabetes incidence over time at varying altitudes while controlling for these confounders. The cross-sectional designs used in the U.S. altitude research, which examined obesity and metabolic outcomes by elevation, and the Andean ecological analyses, which linked national survey data to altitude in multiple South American regions, capture a snapshot rather than a causal chain. Researchers have not yet demonstrated in humans that boosting red blood cell production through hypoxia exposure or EPO directly improves glucose tolerance independent of other metabolic changes such as weight loss or increased energy expenditure.
The therapeutic angle also remains early-stage. A small molecule sometimes described as an altitude mimetic, which left-shifts hemoglobin oxygen affinity to mimic some tissue-level effects of high elevation, has shown experimental validation in preclinical settings. But no human trial data exist to confirm whether such a drug could safely and effectively lower blood sugar in people with or at risk for diabetes. EPO itself carries well-documented risks, including blood clots, hypertension, and cardiovascular events, that would complicate any straightforward translation from mouse results to patient care. Any attempt to harness red blood cell–driven glucose uptake would have to balance potential glycemic benefits against the dangers of excessive hematocrit.
There is also a conceptual gap between the two lines of mouse research. The Cell Metabolism study emphasizes that newly produced red blood cells are the key actors because they carry more GLUT1 transporters and show heightened glycolytic activity. The Vienna group’s experiments, published in Science Advances, suggest that simply increasing total red blood cell mass, regardless of how new the cells are, lowers blood glucose. Whether the effect depends on cell age, transporter density, or sheer volume of circulating red blood cells has not been resolved. It is possible that both mechanisms contribute: a spike in young, GLUT1-rich cells during hypoxia, and a more general capacity of red blood cells to siphon off glucose when present in larger numbers.
How to read the evidence
The strongest pieces of this story rest on peer-reviewed primary research. The Cell Metabolism paper provides direct experimental evidence of the GLUT1-mediated glucose uptake mechanism in red blood cells under hypoxia, using carefully controlled mouse models and molecular assays. The Science Advances study independently confirms that raising hematocrit lowers glycemia in mice through multiple experimental methods, lending robustness to the basic observation that more red blood cells can mean less circulating sugar.
The epidemiological studies from the U.S. and Andean populations sit one tier below in evidentiary strength. The U.S. work based on National Health and Nutrition Examination Survey data and additional altitude–metabolism analyses use large, nationally representative samples and adjust for several key confounders, but they remain observational. The Peruvian and Colombian data sets extend the pattern to different ethnic and cultural contexts, and the South American analyses attempt to account for regional variation in lifestyle and access to care. Still, none of these designs can rule out unmeasured factors that might drive both where people live and their risk of diabetes.
For now, the most cautious reading is that high altitude appears to be associated with lower type 2 diabetes prevalence, and that hypoxia clearly changes how red blood cells handle glucose in animal models. The mechanistic work makes the epidemiological pattern more biologically plausible, but it does not convert association into proof of causation. Future research will need to bridge that gap with carefully designed human studies, potentially including short-term hypoxia exposures, trials of altitude-mimicking drugs with close hematologic monitoring, and long-term cohort studies that follow people who move between elevations.
If those efforts bear out the early promise, the implications could extend beyond people who live in the mountains. A controllable “altitude effect” on red blood cells might one day become another tool for managing blood sugar, used alongside diet, exercise, and existing medications. Until then, the new findings are best understood as a compelling piece of the diabetes puzzle rather than a ready-made prescription to seek higher ground.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
